Xeris Pharmaceuticals (XERS)
(Real Time Quote from BATS)
$2.78 USD
-0.15 (-5.12%)
Updated Sep 23, 2024 02:20 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Xeris Biopharma Holdings, Inc. [XERS]
Reports for Purchase
Showing records 1 - 18 ( 18 total )
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
2Q24: Recorlev Confidence Increasing; Base Biz Undervalued With Free Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
Phase 2 Confirms Dose Conversion for Potential Levothyroxine Weekly SC Injection; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
1Q24: Steady Operational Execution Across the Board; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
4Q23: Negative Strock Reaction Unmerited; We Actually Raise Target to $6; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
3Q23: Inching Closer to Break-Even; Lower PT to $5.50 on Moderated Recorlev Ramp, but Reiterate Buy at These Levels
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
2Q23: Another Revenue Beat; Guidance Midpoints Raised; Recorlev Ramping; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
1Q23: Another Strong Beat to Start the Year; Reiterate Buy and $6 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
Wide But Strong 2023 Revenue Guide, With Renewed Promise of 4Q23 Cash Flow Breakeven; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
3Q22: Solid Performance Across Portfolio; Xeris Reiterates Cash Runway Through Profitability; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
Weekly Levothyroxine Injection POC Established; Early Days But Could Prove Xeris? Largest Opportunity Yet; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
2Q22: Bottom Line Beat on Operating Margins; Affirmed Strong Guide; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
1Q21 In Line With Our Estimates; Strong 2022 Guide Reiterated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
Solid 4Q Sales, 2022 Guide, and Ambitious End-2023 Cash Flow Breakeven Goal; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
Recorlev Launching Now With Comprehensive Patient Support Services; Raise PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
Happy New Year Indeed, With Credibility Boosting Recorlev Approval; Raise Target Price
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
3Q21: Solid Gvoke and Pro Forma Performance; Look Forward to Jan 1 Recorlev PDUFA; PT to $4.25
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
We initiate coverage with a Buy rating and $4 price target
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Xeris Biopharma Holdings, Inc.
Industry: Medical - Drugs
|